Bethany A Gray, Olivia L Bolts, Deborah Fidler, Mark Prince
{"title":"Identifying Three Psilocybin Use Patterns by Frequency and Quantity.","authors":"Bethany A Gray, Olivia L Bolts, Deborah Fidler, Mark Prince","doi":"10.15288/jsad.23-00312","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Patterns of psilocybin use in non-clinical settings are not well described in the literature. Psilocybin use can involve infrequent, large (i.e., macro) doses that produce hallucinogenic effects. In addition, some people report psilocybin use at particularly small (i.e., micro), sub-perceptual doses. Given the heterogeneity in reported use metrics, we sought to determine whether there are identifiable patterns of psilocybin use based on participants' self-described typical use frequencies and quantities and to describe how demographic characteristics are associated with each pattern of use.</p><p><strong>Method: </strong>Participants were recruited from online communities via Reddit.com. We used Latent Profile Analysis to discern psilocybin use patterns defined by frequency and quantity of use. The analytic sample consisted of 664 participants (75.6% US residents; 83.1% white; 67.2% male).</p><p><strong>Results: </strong>The Chipper Profile (18%) was associated with approximately 1-4 annual uses and using between 0.75g and 1.0g of dehydrated, psilocybin-containing mushrooms. The Tripper Profile (64%) was associated with approximately 2-6 annual uses and self-reported use quantities between 2-4g. The Microdoser Profile (18%) was related to substantively higher psilocybin use frequencies than the other profiles (between 2-4 times a week) and a lower range of preferred quantities (between 0.25g - 0.75g). Additionally, profiles differed by certain demographic measurements, lifetime psilocybin use, and timing of psilocybin use.</p><p><strong>Conclusions: </strong>Psilocybin use in non-clinical settings is heterogeneous. We identified three profiles that differed on frequency and quantity of use and their associated demographic characteristics. Next steps are to identify factors that affect one's likelihood of experiencing particular use outcomes and to explore use variability.</p>","PeriodicalId":17159,"journal":{"name":"Journal of studies on alcohol and drugs","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of studies on alcohol and drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15288/jsad.23-00312","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Patterns of psilocybin use in non-clinical settings are not well described in the literature. Psilocybin use can involve infrequent, large (i.e., macro) doses that produce hallucinogenic effects. In addition, some people report psilocybin use at particularly small (i.e., micro), sub-perceptual doses. Given the heterogeneity in reported use metrics, we sought to determine whether there are identifiable patterns of psilocybin use based on participants' self-described typical use frequencies and quantities and to describe how demographic characteristics are associated with each pattern of use.
Method: Participants were recruited from online communities via Reddit.com. We used Latent Profile Analysis to discern psilocybin use patterns defined by frequency and quantity of use. The analytic sample consisted of 664 participants (75.6% US residents; 83.1% white; 67.2% male).
Results: The Chipper Profile (18%) was associated with approximately 1-4 annual uses and using between 0.75g and 1.0g of dehydrated, psilocybin-containing mushrooms. The Tripper Profile (64%) was associated with approximately 2-6 annual uses and self-reported use quantities between 2-4g. The Microdoser Profile (18%) was related to substantively higher psilocybin use frequencies than the other profiles (between 2-4 times a week) and a lower range of preferred quantities (between 0.25g - 0.75g). Additionally, profiles differed by certain demographic measurements, lifetime psilocybin use, and timing of psilocybin use.
Conclusions: Psilocybin use in non-clinical settings is heterogeneous. We identified three profiles that differed on frequency and quantity of use and their associated demographic characteristics. Next steps are to identify factors that affect one's likelihood of experiencing particular use outcomes and to explore use variability.
期刊介绍:
The Journal of Studies on Alcohol and Drugs began in 1940 as the Quarterly Journal of Studies on Alcohol. It was founded by Howard W. Haggard, M.D., director of Yale University’s Laboratory of Applied Physiology. Dr. Haggard was a physiologist studying the effects of alcohol on the body, and he started the Journal as a way to publish the increasing amount of research on alcohol use, abuse, and treatment that emerged from Yale and other institutions in the years following the repeal of Prohibition in 1933. In addition to original research, the Journal also published abstracts summarizing other published documents dealing with alcohol. At Yale, Dr. Haggard built a large team of alcohol researchers within the Laboratory of Applied Physiology—including E.M. Jellinek, who became managing editor of the Journal in 1941. In 1943, to bring together the various alcohol research projects conducted by the Laboratory, Dr. Haggard formed the Section of Studies on Alcohol, which also became home to the Journal and its editorial staff. In 1950, the Section was renamed the Center of Alcohol Studies.